31 August 2026
Four obesity drugs show no extra respiratory harm versus placebo
Liraglutide, semaglutide, tirzepatide and naltrexone-bupropion had no higher respiratory adverse-event risk in a 122-study systematic review and meta-analysis.
The full briefing is in the app.